|
Jun 18
|
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City
|
|
Apr 8
|
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
|
|
Jan 4
|
Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide in Treatment-resistant Schizophrenia (TRS)
|
|
Dec 29
|
Newron Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A With Evenamide
|